---

Peptide therapy: what is actually legal, and what is not

Peptide therapy is one of the most marketed things in my field right now, and one of the most misrepresented. In two decades of practicing medicine I have rarely seen a gap this wide between what patients are told and what is actually true. So let me lay it out honestly, including the parts that are inconvenient for clinics that sell these.

First, what a peptide is

A peptide is a short chain of amino acids — smaller than a protein, larger than a single building block. Your body makes thousands of them, and they act as signals: telling tissue to grow, appetite to fall, hormones to release. Under U.S. law, a peptide of 40 amino acids or fewer is regulated as a small-molecule drug. Longer chains are regulated as biologics. That distinction sounds academic until you realize it determines what is legal.

Important context that gets lost: peptides are not fringe medicine. Somewhere around 80 to 100 peptide drugs are FDA-approved and on the market, covering diabetes and obesity, cancer, endocrine disease, bone disease, and infection. Semaglutide and tirzepatide are peptides. So is insulin. So the question is never "are peptides real?" The question is always "which one, and is it approved?"

The four-tier reality

Category	Legal status	Example
FDA-approved product, used on-label	Fully legal	Semaglutide for type 2 diabetes or obesity
FDA-approved product, used off-label	Legal at physician discretion with sound justification	An approved peptide used for a related condition
Compounded from an approved drug or a permitted bulk substance	Legal only if the substance qualifies under section 503A or 503B	Many marketed peptides do not qualify
Unapproved "research" peptides	Not legally prescribable	BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, epitalon, melanotan II

That bottom row is what most people mean when they say "peptide therapy." Those compounds have no FDA approval. They are sold as research chemicals or supplement-adjacent products, often labeled for research use only, not for human use. A product carrying that label is not lawful to prescribe or give to a patient. In 2023 the FDA placed most of them in the category of bulk substances that may present significant safety risks, which barred compounding pharmacies from using them.

If you want the plain-English version of that table — every approved peptide that comes up in my office, what each one is approved for, where every gray-market name stands today, and what actually goes wrong inside a badly made vial — read which peptides are FDA-approved, which are not, and why the pharmacy matters more than the peptide.

What actually happened in 2026

You may have seen headlines saying peptides are now legal. They are not, and the gap between the headline and the law is where people get hurt.

In April 2026, the FDA removed about a dozen gray-market peptides from the significant-safety-concerns list. That sounds like vindication, but the reason was procedural: the outside parties who had nominated them withdrew their requests. Two patient-safety organizations noted publicly that the removal was not accompanied by, and did not result from, new scientific evidence.

Then on July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides and recommended six of them — BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon — for the list of substances compounding pharmacies may use. Emideltide was the only rejection. The votes were narrow, mostly 8 to 6.

Three things about that vote deserve to be said plainly:

• The FDA’s own scientists recommended against all seven. They cited incomplete chemical characterization, thin human clinical data, and concerns about immune reactions. The panel voted the other way anyway.
• The vote is not binding and it is not approval. The market keeps treating three separate legal events as one. Removal from the restricted category is one thing. An advisory recommendation is another. Actual placement on the permitted-compounding list requires formal notice-and-comment rulemaking, which typically takes eight to twelve months. Until that finishes, nothing has changed.
• This is not the same as FDA drug approval. Even if these end up compoundable, that means a pharmacy may prepare them — not that they have been shown to work or to be safe. No efficacy trial has to be passed to get on that list.

Separately, and moving in the opposite direction: on April 30, 2026, the FDA proposed barring outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk, on the reasoning that approved products already exist.

The problem nobody advertises

Here is the detail from the FDA’s presentation that I cannot stop thinking about. Agency staff reported encountering multiple substances all sold as "BPC-157" that contained different active molecules. There is no universally accepted chemical definition for several of these compounds. The name on the vial does not reliably tell you what is in the vial.

Think about what that means for anyone buying online. You are not choosing a dose of a known substance. You are injecting an unverified molecule from an unregulated supply chain, and if you have a reaction, nobody — including your doctor — can say for certain what you took. That is a different category of risk than "this might not work."

Credit where it is due: the argument on the other side is real. People are already buying these from overseas suppliers and corner stores, and supporters argue that regulated compounding pharmacies would at least be safer than that. I understand the logic. I do not think it justifies telling a patient a compound is proven when it is not.

Where I stand

We prescribe approved peptides where they are indicated and where your labs support it. GLP-1 medications are peptide therapy, they are approved, they are extensively studied, and they are working in my patients right now.

We do not sell unapproved research peptides, and we will not while they sit outside the law with no established safety or efficacy data. If a clinic offers you BPC-157 or TB-500 today, ask them directly what its current legal status is. The answer will tell you a great deal about how they practice.

I am not against these compounds. I follow this closely, and if the rulemaking finishes and real safety data arrives, we will offer them properly. What I will not do is get ahead of the evidence with your body.

Measure, don’t guess

Most people asking about peptides are chasing something specific: healing that has stalled, energy that is gone, weight that will not move, sleep that does not restore. Those have causes, and the causes are measurable. Hormones, thyroid, blood sugar, inflammation, and nutrient status explain far more of it than any compound from an unlabeled vial will. Related reading: which peptides are FDA-approved, which are not, and why the pharmacy matters more than the peptide, peptide risks: what is actually in the vial, what actually heals a tendon, GLP-1 benefits beyond weight loss, essential amino acids and glycine, what is retatrutide, and signs you may need hormone replacement.

Text us at 480-485-2197 to schedule, or call. Quick response, real scheduling, no phone tree.

To Health and Wellness,
Dr. Tallman

---

References

This page covers general health information and is not a substitute for individual medical advice. Regulatory status changes; this page reflects the situation as of its last update, and current status should be confirmed on the FDA’s compounding bulk substances pages. Never obtain or inject a prescription-type substance from an unapproved source.

• JAMA, 2026 — under FDA, unapproved peptides likely to become more widely available.
• U.S. Food and Drug Administration, July 23–24, 2026 — Pharmacy Compounding Advisory Committee meeting materials, 503A bulk drug substances.
• Journal of Clinical Pharmacology, 2025 — review of clinical pharmacology information for peptides in US FDA drug labeling.
• Nature Reviews Drug Discovery, 2021 — trends in peptide drug discovery.
• Biomolecules, 2024 — FDA-approved peptide analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and alpha-MSH families.
• Chemical Biology & Drug Design, 2023 — peptide-based diagnostic and therapeutic agents.
• Cancer Medicine, 2026 — biopharmaceuticals for cancer treatment: an update.